SpyGlass Pharma, Inc. (SGP) stock
SGPNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$31.43−0.81 (-2.50%)
Close on Nov 17, 2026Market cap $1.05BP/E –Yield –
SpyGlass Pharma r&d expenses
Research and development expenses are spending on new products and technology.
For fiscal 2025 it was $29.18M, up 46.0% from the year before.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $29.18M | +46.0% |
| FY2024 | Dec 31, 2024 | $19.98M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $10.94M | – |
| Q1 FY2026 | Mar 31, 2026 | $8.54M | – |
| Q2 FY2025 | Jun 30, 2025 | $7.33M | – |
| Q1 FY2025 | Mar 31, 2025 | $6.05M | – |
See a number that looks wrong?